Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis

O’Rielly, Darren D.; Rahman, Proton

doi:10.1016/j.rdc.2015.07.002

Cited by 56 publications

(54 citation statements)

References 154 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concerning the environmental risk factors, it is important to mention: stress, low-humidity, drugs, smoking, obesity and chronic infections. In addition, numerous susceptibility genes and variants (LCE3B, LCE3C, TRAF3IP2, polymorphisms in IL-17, IL-23, RUNX3 and TNF*-857) have been recognized as contributing risk factors for PsA [15,[18][19][20][21][22][23][24]. Concerning the treatment of PsA, the available therapeutic approaches are mainly oriented to relief the inflammation and/or the associated-symptoms and to 'slow-down' the progression to more advanced and severe stages of the disease.…”

Section: Pharmacogenomics and Psoriatic Arthritismentioning

confidence: 99%

“…The main advantage of these new drugs is the possibility of oral administration, in contrast with the traditional biological drugs, which are released by intravenous infusion or injection [36]. Approximately 20-40% of treated patients present variable responses to the TNF-α inhibitors, which have been linked to the presence of polymorphisms in the TNF-α gene (6p21.33) [15,24,[35][36][37]. However, significant PGx data are available for etanercept and infliximab, up to date.…”

Section: Biological Drugsmentioning

confidence: 99%

“…The FCGR2A gene (1q23.3) codes for an Fc receptor protein and is localized on the cell surface, where it mediates the phagocytosis mechanisms and the elimination of the immune complexes [24,41].…”

Section: Biological Drugsmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacogenomics of Multifactorial Diseases: A Focus on Psoriatic Arthritis

et al. 2016

View full text Add to dashboard Cite

This review will outline the current pharmacogenomics knowledge about psoriatic arthritis with a special attention to the perspectives and the challenges for its implementation in the clinical practice. To date, different drugs have been developed to contrast the symptoms and the progression of psoriatic arthritis. However, patients have shown high variability of drug response in relation to their genetic makeup. In this context, the advances made in the knowledge and the potentialities of genome-drugs associations paved the path for the development of a precision medicine. In fact, these associations may be successfully combined with the environment information to provide new strategies able to prevent and improve the disease management as well as to enhance the patients quality of life.

show abstract

Section: Pharmacogenomics and Psoriatic Arthritismentioning

confidence: 99%

Section: Biological Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacogenomics of Multifactorial Diseases: A Focus on Psoriatic Arthritis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Отмечено, что HLA-Cw6, а также гены, связанные с экспрессией ИЛ12, ИЛ23, ФНОα, являются общими для Пс и ПсА [27,28].…”

Section: результатыunclassified

The Pattern of Cardiovascular Comorbidity in Patients With Severe Forms of Psoriasis: Data of Retrospective Analysis of a Hospital Cohort

Баткаева¹,

Коротаева²,

Баткаев³

2017

rsp

View full text Add to dashboard Cite

“…Regarding genetic aspects, the dominant psoriatic disease susceptibility sequences have been identified in several regions located within the MHC 6 . In particular, HLA-Cw0602 has been shown to be associated with cutaneous manifestations and the HLA-B*27 allele with severe articular phenotypes, mainly with the psoriatic spondyloarthritis subset 7,8 .…”

mentioning

confidence: 99%